INONasdaqPharmaceutical PreparationsFiscal year ends December 31
INOVIO PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.00+0.01 (+1.00%)
Close on Oct 19, 2026
- Market cap
- $81.62M
- P/E (TTM)
- –
- Dividend yield
- –
INOVIO PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q2 22 | TTM Q1 22 | TTM Q4 21 | TTM Q3 21 | TTM Q2 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue under collaborative research and development arrangements with affiliated entities | – | – | – | – | – | – | – | – | $204.20K | $245.31K | $302.65K | $311.19K | – | – |
| Revenue under collaborative research and development arrangements, including from affiliated entities | – | – | – | – | – | – | – | $882.46K | $928.54K | $902.26K | $5.21M | $5.15M | – | – |
By region
From the segment and revenue-disaggregation notes of Inovio Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.